www.fgks.org   »   [go: up one dir, main page]

This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!
Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Dec 4;40(Suppl 3):7-23.
doi: 10.14745/ccdr.v40is3a02.

Canadian Adverse Events Following Immunization Surveillance System (CAEFISS): Annual report for vaccines administered in 2012

Affiliations
Free PMC article

Canadian Adverse Events Following Immunization Surveillance System (CAEFISS): Annual report for vaccines administered in 2012

B J Law et al. Can Commun Dis Rep. .
Free PMC article

Abstract

Background: To describe the adverse event following immunization (AEFI) reporting profile for vaccines administered in Canada during 2012 and surveillance trends relative to reports for vaccines administered from 2005 through 2011.

Methods: Analysis of data based on AEFI reports received by the Public Health Agency of Canada by April 30, 2013, for vaccines marketed in Canada and administered from January 1, 2005, through December 31, 2012.

Results: The AEFI reporting rate was 10.1 per 100,000 population in Canada for vaccines administered in 2012 and was inversely proportional to age. There was a trend of declining rates from 2005 (14.8) to 2012 overall and by age group. The vast majority of reports (94%-95%) were non-serious involving reactions at or near the vaccination site, rash and febrile events.

Conclusion: Canada has a strong pharmacovigilance system for vaccines with one of the highest AEFI reporting rates in developed countries. Vaccines marketed in Canada have a very good safety profile. This report enables comparisons across jurisdictions in Canada and globally.

Conflict of interest statement

Conflict of interest: None

Figures

Figure 1A
Figure 1A. AEFI1 reporting sources for children and adults by year vaccine administered, 2005−2012
1 Adverse event following immunization (AEFI)
Figure 1B
Figure 1B. Serious AEFI1 (SAE)2 reporting sources for children and adults by year vaccine administered, 2005−2012
1 Adverse event following immunization (AEFI)
2 Serious Adverse Event (SAE)
Figure 2
Figure 2. Primary adverse event following immunization (AEFI) distribution by vaccine group

Similar articles

Cited by 11 articles